Accelerating and Streamlining Microbial Process Development With a Novel Technology

Discover how FUJIFILM Biotechnologies’ novel technology speeds gene-to-cGMP for microbial-expressed biologics, integrating with Paveway™ PLUS. Join the webinar to explore the real-world impact on reducing downstream complexity and timelines, enabling a smoother route to toxicology and clinical-grade production.

Register Free: https://www.biopharminternational.com/bp_w/microbial

Event Overview:

The complexity and diversity of microbial-expressed biologics remains a challenge that can lead to costly and time-consuming process development work, particularly during downstream development. While traditional affinity chromatography is the norm for standard antibody-based therapies, there are limited approaches for more complex antibodies, antibody fragments, and nonantibody-based therapies.

Leveraging deep process knowledge across hundreds of microbial-expressed proteins, FUJIFILM Biotechnologies has developed a novel technology to enable rapid and efficient progression from gene to cGMP manufacturing across various microbially expressed modalities.

This technology enables a more standardized affinity-based chromatography approach without the negative effects that some other technologies pose. This approach integrates seamlessly with our established Paveway™ PLUS microbial expression system to deliver high-quality early-stage material suitable for product-quality assessment and provides a direct, scalable pathway toward cGMP-ready processes.

The presentation describes the development of the technology, highlights its workflow advantages, and demonstrates its impact on reducing timelines through reducing manufacturing complexity—ultimately enabling our partners to advance smoothly toward toxicology and clinical-grade material production.

Key Learning Objectives

• Understand the current challenges of microbial process development
• Learn about a new innovation/technology to ensure competitive PD timelines and de-risk manufacturing by reducing rate of failure
• Understand the timelines from process development to GMP manufacture

Who Should Attend

• Professionals involved in:
• Process development
• Early-phase microbial projects
• Purification of small proteins (<10kDa)
• Proteins that are difficult to purify

Speaker:

Andrei Soliakov, PhD
Principal Technical Project Lead Process Development
FUJIFILM Biotechnologies

Andrei Soliakov, PhD, is a principal technical project lead within the Process Development Group at FUJIFILM Biotechnologies in the United Kingdom. Soliakov is responsible for overseeing process development and GMP manufacturing of early-phase microbial projects and offering technical design and support to prospective partners. His professional background spans more than a decade working with downstream purification and characterization of proteins in various environments, including academic institutions, start-ups, and CDMOs. Andrei earned a PhD in structural biochemistry and molecular biophysics from Newcastle University and a BSc in biochemistry from the University of Bath.

Register Free: https://www.biopharminternational.com/bp_w/microbial